Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Authors: Kelloff GJ,  Lippman SM,  Dannenberg AJ,  Sigman CC,  Pearce HL,  Reid BJ,  Szabo E,  Jordan VC,  Spitz MR,  Mills GB,  Papadimitrakopoulou VA,  Lotan R,  Aggarwal BB,  Bresalier RS,  Kim J,  Arun B,  Lu KH,  Thomas ME,  Rhodes HE,  Brewer MA,  Follen M,  Shin DM,  Parnes HL,  Siegfried JM,  Evans AA,  Blot WJ,  Chow WH,  Blount PL,  Maley CC,  Wang KK,  Lam S,  Lee JJ,  Dubinett SM,  Engstrom PF,  Meyskens FL Jr,  O'Shaughnessy J,  Hawk ET,  Levin B,  Nelson WG,  Hong WK,  AACR Task Force on Cancer Prevention
Journal: Clin Cancer Res
Date: 2006 Jun 15
Branches: OEEB
PubMed ID: 16778094
PMC ID: not available
Abstract: This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.